Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-122495
Filing Date
2025-05-19
Accepted
2025-05-19 16:45:32
Documents
18
Effectiveness Date
2025-05-19

Document Format Files

Seq Description Document Type Size
1 S-8 d934315ds8.htm S-8 62793
2 EX-5.1 d934315dex51.htm EX-5.1 5792
3 EX-23.1 d934315dex231.htm EX-23.1 1567
4 EX-99.2 d934315dex992.htm EX-99.2 30282
5 EX-99.4 d934315dex994.htm EX-99.4 35321
6 EX-FILING FEES d934315dexfilingfees.htm   iXBRL EX-FILING FEES 20598
7 GRAPHIC g934315g0517025605752.jpg GRAPHIC 2695
8 GRAPHIC g934315g0517025605886.jpg GRAPHIC 4906
  Complete submission text file 0001193125-25-122495.txt   307929

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT d934315dexfilingfees_htm.xml XML 12521
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-287402 | Film No.: 25964660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)